scholarly journals A Case of Repeated Salvage Lymphadenectomy for Abdominal Lymph Node Recurrence following Definitive Chemoradiotherapy for Esophageal Cancer

2016 ◽  
Vol 77 (8) ◽  
pp. 1957-1963
Author(s):  
Hironori FUJIEDA ◽  
Masahide FUKAYA ◽  
Kazushi MIYATA ◽  
Yayoi SAKATOKU ◽  
Masato NAGINO
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Definitive Chemoradiotherapy ◽  
Abdominal Lymph Node ◽  
Lymph Node Recurrence ◽  
Salvage Lymphadenectomy

Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer

Esophagus ◽  
2014 ◽  
Vol 11 (3) ◽  
pp. 197-203 ◽  
Author(s):  
Satoru Matono ◽  
Hiromasa Fujita ◽  
Toshiaki Tanaka ◽  
Naoki Mori ◽  
Takeshi Nagano ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Nodes ◽  
Definitive Chemoradiotherapy ◽  
Salvage Lymphadenectomy

scholarly journals Salvage Lymphadenectomy for Recurrent Esophageal Cancer After Chemoradiotherapy

2014 ◽  
Vol 99 (4) ◽  
pp. 452-457 ◽  
Author(s):  
Masanobu Nakajima ◽  
Yasushi Domeki ◽  
Hitoshi Satomura ◽  
Masakazu Takahashi ◽  
Akira Sugawara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Disease Progression ◽  
R0 Resection ◽  
Cervical Node ◽  
Salvage Lymphadenectomy

Abstract Although salvage esophagectomies are widely performed, reports on salvage lymphadenectomy (SL) are few. We review our SL cases to clarify the indications. Fifty-five patients with esophageal cancer underwent chemoradiotherapy or radiotherapy, including 3 patients with single lymph node (LN) recurrences and one with allochronic double cervical node recurrence. Our department removed 5 recurrent LNs from these 4 patients. In Case 1, right supraclavicular LN was judged to be metastatic and R0 resection was carried out; he is alive without recurrence. In Case 2, we found, allochronically, metastases in his left cervical paraesophageal LN and left supraclavicular LN; residual tumors were R1 in both lesions. He is alive despite esophageal recurrence. In Case 3, a lymphadenectomy was performed on his thoracic para-aortic LN; however, tumor was removed incompletely, and he died 4 months after SL from disease progression. In Case 4, a subcarinal LN was thought to be metastatic, and was removed but no malignant tissues detected. He died 17 months after SL from pneumonia. Our experiences suggest that some patients survive relatively long with SL. Moreover, molecular examination of resected lesions could guide subsequent therapies. SL might be more widely used for these patients if not otherwise contraindicated.

Successful salvage lymphadenectomy after stent grafting for aortic lymph node recurrence of thoracic esophageal carcinoma: a first case report

Esophagus ◽  
2014 ◽  
Vol 12 (3) ◽  
pp. 312-315
Author(s):  
Tomotaka Shibata ◽  
Tsuyoshi Noguchi ◽  
Tsuyoshi Etoh ◽  
Masafumi Inomata ◽  
Norio Shiraishi ◽  
...  
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Esophageal Carcinoma ◽  
Stent Grafting ◽  
Lymph Node Recurrence ◽  
First Case ◽  
Aortic Lymph Node ◽  
Salvage Lymphadenectomy

PS02.031: DEFINITIVE CHEMORADIOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL (DCF-R) FOR ADVANCED CERVICAL ESOPHAGEAL CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 128-129
Author(s):  
Hiroshi Okamoto ◽  
Yusuke Taniyama ◽  
Tadashi Sakurai ◽  
Takahiro Heishi ◽  
Chiaki Sato ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Lymph Node ◽  
Survival Rate ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Conflicts Of Interest ◽  
Clinical Stage ◽  
Stage Ii ◽  
Definitive Chemoradiotherapy

Abstract Background Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. There have been recent reports on favorable outcomes of docetaxel/CDDP/5-FU (DCF-R) for advanced esophageal cancer. Our department recently introduced DCF-R for treating advanced cervical ESCC. We analyzed the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods We retrospectively evaluated 12 advanced cervical ESCC patients (clinical stage II–IV, including T4b and/or M1 lymph node) in our department who received DCF-R as the first-line treatment between December 2010 and February 2015. Results Our patient cohort comprised 9 males and 3 females (median age, 67.5 years; range: 54–76 years). All patients were squamous cell carcinoma. The median observation period was 34.5 (8–80) months with total irradiation dose of 64.0 (60–70) Gy. The pretreatment clinical stage (according to Union for International Cancer Center) included one stage II, seven stage III, and four stage IV cases (including 3 patients with T4b [2 trachea and 1 thyroid] and 4 patients with M1 lymph node. We attained complete response (CR) in 10 patients and stable disease in 2 patients. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Two persistent patients included one patient who died of cancer and one patient who underwent salvage surgery. Furthermore, grade 3 or more adverse events as defined in Common Terminology Criteria for Adverse Event version 4 included leucopenia (91.7%), neutropenia (91.7%), febrile neutropenia (50%), and pharyngeal pain (50%). There was no treatment-related mortality and treatment schedules were completed in all patients, although dose reduction of the second cycle of chemotherapy was required in four patients (33%) and change in the radiation schedule was required in one patient (8.3%). While the 2-/3-/5-year overall survival rate was 66.7%/48.6%/48.6%, the 2-/3-/5-year recurrent-free survival rate was 58.3%/50.0%/37.5%, respectively. Conclusion DCF-R treatment for advanced cervical ESCC could be completed by the careful administration, and although a strong blood toxicity might occur, a favorable prognosis can be obtained with larynx preservation. Disclosure All authors have declared no conflicts of interest.

Sign in / Sign up

Export Citation Format

Share Document